

**Supplementary Table S1. Comparison of CART19/20 cell therapy results with reported data from trials evaluating other CD19/CD20 bispecific CAR-T cell therapies and commercially available CD19 CAR-T cell therapies.**

CAR Type	Trial	ORR	CR Rate	Median PFS	CRS	ICAMS	Notes on Cell Manufacturing	Reference
CD19/CD20 CAR	UCLA	90% (9/10)	Overall 70% (7/10)	Not Reached (median follow-up = 17 months)	66% overall all grade 1	None	All products cryopreserved; 11 patients underwent leukapheresis and 10 dosed (91%)	This Study
			36M–58M: 57% (4/7); 1 (25%) relapse) 146M–165M: 100% (3/3)					
CD19/CD20 CAR	Medical College of Wisconsin	82% (18/22)	Overall: 64% (14/22); 29% (2/7) with cryopreserved products	9.1 months	64% overall 5% grade 3+	32% overall 14% grade 3+	7 patients dosed with cryopreserved products; 15 patients dosed with fresh products; 26 patients underwent leukapheresis and 22 dosed (85%)	Shah et al., Nat. Med., 2020
			17.5M: 33% (1/3)					
			52.5M: 33% (1/3); 1 (100%) relapse)					
			175M: 75% (12/16; 4 (33%) relapse)					
CD19/CD20 CAR	Chinese PLA General Hospital	80% (70/87)	Overall: 70% (61/87)	27.6 months	70% overall 10% grade 3+	17% overall 2% grade 3	All products cryopreserved; 92 patients underwent leukapheresis and 87 dosed (95%)	Zhang et al., Leukemia, 2021
			39M–55M: 100% (2/2)					
			126M–196M: 61% (11/18; 4 (36%) relapse)					
			203M–294M: 68% (17/25; 7 (41%) relapse)					
			308M–378M: 69% (9/13; 3 (33%) relapse)					
CD19 CAR	ZUMA1	83% (84/101)	Overall: 58% (59/101) Target dose: 2M/kg = 140M for 70-kg patient	5.9 months	93% overall 11% grade 3+	67% overall 32% grade 3+	All products cryopreserved; 119 patients enrolled and 108 dosed (91%)	Locke et al., Lancet, 2018
			413M–560M: 76% (22/29; 4 (18%) relapse)					
CD19 CAR	JULIET	53% (61/115)	Overall: 39% (45/115) Target dose: 500M	2.9 months	57% overall 23% grade 3+	20% overall 11% grade 3+	All products cryopreserved; 167 patients enrolled and 115 dosed (69%)	Schuster et al., Lancet, 2021
CD19 CAR	TRANSCEND NHL 001	73% (186/256)	Overall: 53% (136/256)	6.8 months	42% overall 2% grade 3+	30% overall 10% grade 3+	All products cryopreserved; 344 patients underwent leukapheresis and 294 dosed (85%)	Abramson et al., Lancet, 2020
			50M: 60% (24/40)					
			100M: 52% (88/169) 150M: 51% (21/41)					